AExcellent

Regeneron Pharmaceuticals, Inc.(REGN)

A

Financial data as of Dec 31, 2025Stable · Healthcare

FCF Margin19.3%Free Cash Flow / Revenue
Cash Conversion110.5%Operating CF / Net Income
Free Cash Flow$3.8B
Revenue$14.3B
Net Cash$412.2MCash exceeds debt
Debt / FCF1.0xManageable debt load
Current Ratio4.13Adequate short-term liquidity
YoY FCF Growth+4.7%5 of 5 quarters positive

How This Grade Was Calculated

Base grade from FCF margin, adjusted by financial health factors

BaseA
+0.5Healthy FCF margin with manageable debt (19.3%, 1.0x)
+1Net cash position with strong FCF margin
+1Very low debt-to-FCF ratio (1.0x)
+0.25Solid revenue growth (19.0% YoY)
FinalA

Analysis Summary

Strengths

  • Strong FCF margin (19.3%)
  • Excellent cash conversion (111%)
  • Net cash position ($0.4B)
  • Very low debt relative to cash flow (1.0x)
  • Strong liquidity (current ratio: 4.13)
SBC-adjusted FCF used — $1.0B stock-based compensation (26% of reported FCF) subtracted

Financial Breakdown

Key financials compared side by side

Margin Composition

FCF Margin19.3%
Net Margin31.4%
Operating CF Margin34.7%
CapEx Ratio8.5%

Balance Sheet Health

Debt, liquidity, and leverage snapshot

Net Cash$412.2MCash exceeds debt
Debt / FCF1.0xManageable debt load
Current Ratio4.13Strong liquidity
Debt / Equity0.09Low leverage

Quarterly FCF Trend

+4.7% YoYStable (+4.7%)

Free cash flow per quarter

Sector Comparison — Healthcare

FCF Margin ranked against sector peers

View all →

Detailed Metrics

Company NameRegeneron Pharmaceuticals, Inc.
SectorHealthcare
Free Cash Flow$3.8B
Revenue$14.3B
Net Income$4.5B
Operating Cash Flow$5.0B
Capital Expenditure$1.2B
FCF Margin19.3%
Cash Conversion Rate110.5%
Net Margin31.4%
Total Debt$2.7B
Total Cash$3.1B
Net Cash$412.2M
Current Ratio4.13
Debt / Equity0.09
Debt / FCF1.0x
YoY FCF Growth+4.7%
Positive Quarters5 of 5
Trend DirectionStable
Report DateDec 31, 2025
GradeA
Data SourceYahoo Finance